Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3BNC117 + albuvirtide after interruption of oral ART in virologically suppressed HIV-1 infection
CTR20210795Phase 2Terminated
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Jul 2021
- Modality
- Peptides, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Teropavimab, albuvirtide in Human immunodeficiency virus infection type 1, sponsored by Frontier Biotechnologies Inc.. Started Jul 2021; status: terminated.
02
Drugs
Teropavimabalbuvirtide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on CTR20210795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210795.